Keros Therapeutics (KROS) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Keros Therapeutics (KROS) over the past year, losing 2.7% versus a loss of 25.9%. Over five years, LFCR leads with a -34.3% price change compared with -69.4% for KROS. Lifecore Biomedical is the larger company by market cap ($244.5 million vs $236.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KROS | LFCR |
|---|---|---|
| Share price | $11.95 | $6.45 |
| Market cap | $236.93M | $244.49M |
| 1-day change | +2.66% | +0.31% |
| YTD return | -41.31% | -21.15% |
| 1-year return | -25.87% | -2.71% |
| 5-year return | -69.35% | -34.25% |
| EPS (TTM) | $-3.22 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.55 | $8.98 |
| 52-week low | $9.69 | $3.63 |
| Distance from 52-week high | -47.01% | -28.17% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +65.94% | -2.64% |
| Average volume | 193.04K | 298.38K |
| Shares outstanding | 19.83M | 37.91M |
| Employees | 92 | 382 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed KROS by 23.2 percentage points over the past year.
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
KROS vs LFCR FAQ
Which is bigger, Keros Therapeutics or Lifecore Biomedical?
Lifecore Biomedical (LFCR) is larger, with a market capitalization of $244.49M compared with $236.93M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, KROS or LFCR?
LFCR returned -2.71% over the past 12 months, compared with -25.87% for KROS (price return, excluding dividends). Past performance does not predict future results.
Are Keros Therapeutics and Lifecore Biomedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.